Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

NCT05945823 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer
Esophageal Adenocarcinoma
Esophageal Squamous Cell Cancer
Siewert Type 1 GEJ Cancer
Pancreatic Cancer

Interventions

DRUG: Futibatinib
DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: 5-FU
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: Levoleucovorin
DRUG: Irinotecan

Sponsor

Taiho Oncology, Inc.